How to manage coagulopathies in critically ill patients

被引：0

作者：

Julie Helms

Toshiaki Iba

Jean Marie Connors

Satoshi Gando

Marcel Levi

Ferhat Meziani

Jerrold H. Levy

机构：

[1] Université de Strasbourg (UNISTRA),Department of Emergency and Disaster Medicine

[2] Faculté de Médecine,Hematology Division

[3] Hôpitaux Universitaires de Strasbourg,Department of Acute and Critical Care Medicine

[4] Service de Médecine Intensive-Réanimation,Division of Acute and Critical Care Medicine, Department of Anesthesiology and Critical Care Medicine

[5] Nouvel Hôpital Civil,Department of Vascular Medicine

[6] INSERM (French National Institute of Health and Medical Research),Department of Medicine

[7] UMR 1260,Department of Anesthesiology, Critical Care, and Surgery

[8] Regenerative Nanomedicine (RNM),undefined

[9] FMTS,undefined

[10] Juntendo University Graduate School of Medicine,undefined

[11] Brigham and Women’s Hospital,undefined

[12] Harvard Medical School,undefined

[13] Sapporo Higashi Tokushukai Hospital,undefined

[14] Hokkaido University Faculty of Medicine,undefined

[15] Amsterdam University Medical Centers,undefined

[16] University College London Hospitals NHS Foundation Trust,undefined

[17] and Cardio-Metabolic Programme-NIHR UCLH/UCL BRC London,undefined

[18] Duke University School of Medicine,undefined

来源：

Intensive Care Medicine | 2023年 / 49卷

关键词：

Disseminated intravascular coagulation; Coagulopathy; Sepsis; Trauma; Hematological disease; Critical care;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Coagulopathy is a severe and frequent complication in critically ill patients, for which the pathogenesis and presentation may be variable depending on the underlying disease. Based on the dominant clinical phenotype, the current review differentiates between hemorrhagic coagulopathies, characterized by a hypocoagulable and hyperfibrinolysis state, and thrombotic coagulopathies with a systemic prothrombotic and antifibrinolytic phenotype. We discuss the differences in pathogenesis and treatment of the common coagulopathies.

引用

页码：273 / 290

页数：17

共 50 条

[21] How do we approach thrombocytopenia in critically ill patients?
Thachil, Jecko
Warkentin, Theodore E.
BRITISH JOURNAL OF HAEMATOLOGY, 2017, 177 (01) : 27 - 38
[22] The ten tips to manage critically ill patients with acute-on-chronic liver failure
Fuhrmann, Valentin
Whitehouse, Tony
Wendon, Julia
INTENSIVE CARE MEDICINE, 2018, 44 (11) : 1932 - 1935
[23] HOW MUCH IS ENOUGH? PROTEIN REQUIREMENTS IN CRITICALLY ILL PATIENTS
Llanes, Abilio Arrascaeta
Garcia-Martinez, Miguel Angel
CHEST, 2019, 156 (04) : 980A - 980A
[24] How to treat severe infections in critically ill neutropenic patients?
Lara Zafrani
Elie Azoulay
BMC Infectious Diseases, 14
[25] How deficient are vitamin D deficient critically ill patients?
Paul Lee
Critical Care, 15
[26] How to treat severe infections in critically ill neutropenic patients?
Zafrani, Lara
Azoulay, Elie
BMC INFECTIOUS DISEASES, 2014, 14
[27] HYPERBARIC OXYGEN THERAPY: HOW SAFE IS IT FOR CRITICALLY ILL PATIENTS?
Lo, Takkin
Song, Cassaundra
Alismail, Abdullah
Terry, Michael
Bland, David
CRITICAL CARE MEDICINE, 2014, 42 (12)
[28] In critically ill patients, how often is their weight estimated and how accurate is that estimate?
D Mathew
C Kirwan
D Dawson
B Philips
Critical Care, 13 (Suppl 1):
[29] How natural light affects critically ill patients with subarachnoid hemorrhage
Zhang, Hongliang
Wu, Jiang
CRITICAL CARE, 2011, 15 (03):
[30] How growth hormone is given to critically ill patients needs to be reassessed
Reactions Weekly, 1999, 775 (1) : 5 - 5

← 1 2 3 4 5 →